Roku’s outlook has recently been updated, as the Fair Value Estimate increased from $105.32 to $110.04 following a fresh review by analysts. This change comes after the Discount Rate edged slightly ...

Get key insights from Aquestive Therapeutics Q3 2025 earnings: Anaphylm launch prep, strong financing, FDA outlook, and market disruption.

Privia Health Group, Inc. offers high-growth potential with recurring revenue model and strong relationships. Learn more ...

As we move into the final stretch of the year, stocks continue to grind higher, with the S&P 500 now up 16% year-to-date.

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, ...

Despite posting extraordinary financial results that shattered expectations, Robinhood Markets witnessed its stock value decline sharply by 7-8%. This counte ...

So I've had these headphones for almost two weeks now. When I got them, I chucked it onto the charger until it said it was ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

We tested the RAD-1 to see if it really performs as both a running shoe and a cross-trainer—and the results impressed us.

Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Altimmune (ALT) to $14 from $15 and keeps an ...

With an average price around $1,000 depending on where you look, the Scuba X1 is positioned as the entry-level option in ...

In the assessment of 12-month price targets, analysts unveil insights for CoreWeave, presenting an average target of $151.73, ...